Dear Eye Care Professional,

As we approach the year’s end, I’d like to take a moment to reflect upon what has been a tremendous year for Bausch + Lomb.

In my new role, I’m fortunate to have been able to increase my exposure to the impressive progress that we make every day in all facets of our organization. Our inherent culture of resourcefulness and continued investment in research and development has driven the introduction of a wide range of new products, each designed to meet your and your patients’ evolving needs. Bausch + Lomb is a fully integrated U.S. eye care business – inclusive of Vision Care, Consumer Health, Surgical and Pharmaceuticals. While each of our business units maintains a strong focus on its respective subset of the eye care industry, we collaborate regularly across functions and disciplines, leveraging ideas and learning from one another in order to take advantage of our distinctive position in the market so we can see beyond the predictable and reimagine ways to protect and enhance sight today and into the future.

Key milestones on our 2018 innovation timeline include:

  • Receiving FDA approval of and launching LUMIFY® redness reliever eye drops, which are already the No.1 eye doctor-recommended product in its category.

  • Gaining approval on an extended wear indication for the Bausch + Lomb ULTRA® family of contact lenses and introducing a new -2.75 cylinder option for Bausch + Lomb ULTRA® for Astigmatism that is provided as a standard offering in fit sets. We also expanded parameters for Biotrue® ONEday contact lenses for Astigmatism, offering more astigmatic patients the convenience of this daily disposable lens option, and added the Boston® scleral lens case, a storage case developed specifically for scleral lenses, to our Specialty Vision Products business.
  • Introducing a new 2.5 mL bottle size of VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%, which provides a one-month supply option to help patients reduce their intraocular pressure, and continuing to make progress in strengthening coverage of the product as part of our ongoing efforts to improve access for your patients. Please see Indication and Important Safety Information for VYZULTA below.
  • Expanding our vitamin portfolio with PreserVision® AREDS 2 Formula Chewable vitamins, an alternative for those patients who may have trouble swallowing pills, and Ocuvite® Blue Light eye vitamins, formulated to help eyes filter blue light emitted by digital devices.
  • Continuing to meet the demand for dry eye symptom relief without the use of preservatives with our new Soothe® Xtra Protection Preservative Free lubricant eye drops.

  • Launching the enVista® toric MX60T intraocular lens (IOL), the company’s first hydrophobic acrylic IOL for astigmatism correction, and the Crystalsert® 2.6 injector (CI-26), designed exclusively for use across the entire diopter range of Crystalens® AO and Trulign® toric IOLs.
  • Introducing the first two applications on the eyeTELLIGENCE™ software platform, a cloud-based infrastructure designed to help eye surgeons and surgical facilities optimize practice efficiency when using the company’s Stellaris Elite™ vision enhancement system.
  • Launching the 25- and 27-gauge Bi-Blade® dual port vitrectomy cutters for the Stellaris Elite™ vision enhancement system, which offer increased flow efficiency and control compared to prior generation guillotine cutters.

Expect much more in 2019. We’ve already filed with the FDA for a new corticosteroid in the treatment of post-operative inflammation and pain following ocular surgery. We also have two clinical trials underway investigating new surgical technologies; a novel ophthalmic viscosurgical device formulation as well as an investigational trifocal IOL, the enVista® MX60EF IOL.

During the second half of the year, we will also launch our latest contact lens technology, Bausch + Lomb ULTRA® Multifocal for Astigmatism. These lenses build upon the success of Bausch + Lomb ULTRA® for Presbyopia and Bausch + Lomb ULTRA® for Astigmatism lenses and will be available as a standard offering in the eye care professional’s fit set. We look forward to providing updates on these as well as on several other projects in progress next year.

Beyond building and enhancing our portfolio, Bausch + Lomb continues to make a positive impact through its ONE by ONE Recycling Program, which is made possible through our collaboration with TerraCycle®. Since launching just two years ago, we’ve recycled a combined total of more than five million units of used contact lenses, blister packs and top foils, saving 31,000 pounds of these used materials from entering our oceans, lakes, streams and landfills.

In closing, I want to express our gratitude for your continued collaboration. Our highest priority is to protect and enhance sight by delivering innovations that will serve your patients and support your needs with integrity and excellence. We take this goal - and your feedback - to heart in everything we do.

On behalf of everyone at Bausch + Lomb, I want to wish you and your families a wonderful holiday season, and continued success and happiness in the New Year.


Joseph Gordon
U.S. President, Bausch + Lomb


VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Click here for full Prescribing Information.

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates except Bi-Blade is a trademark of Medical Instrument Development Laboratories, Inc. used by agreement and TerraCycle is a trademark of TerraCycle, Inc.
© 2018 Bausch & Lomb Incorporated.